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Summary Autopsy, histology and cytology have been
and histology and cytology still are the main diagnos-
tic tools in surgical pathology. During the last two
decades molecular biology gradually has extended
the diagnostic armamentarium. In tumor pathology
molecular biology techniques are used to diagnose
and subclassify tumors, predict response to ther-
apies and identify therapeutic targets. Molecular
pathology has evolved into a novel focus of clinical
pathology and transforms the historically morphology
based discipline. Traditional pathology and molecular
pathology combine and guide tumor therapy.
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Pathologists diagnose neoplastic diseases from tissue
biopsies, surgical specimens and cytology aspirates.
They employ as standard methods light microscopy
of hematoxylin and eosin stained tissue slides and
Giemsa or Papanicolaou stained cytologic smears.
During the last half century the conventional light
microscopy has been supplemented by immunohis-
tology with expanding panels of antibodies [1]. The
tasks for classic tumor pathology are tumor classifica-
tion, grading and staging. There is a growing demand
for molecular tumor subclassification and informa-
tion on prognosis, response to therapy and molecular
therapeutic targets. These demands are increasingly
covered by molecular pathology and require an ex-
tended spectrum of methods. These encompass
molecular biology techniques like polymerase chain
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reaction (PCR), DNA and RNA sequencing, flurores-
cence in situ hybridization and gene array assays.
The success of therapies that target genetic alter-
ations has initially been demonstrated by imatinib
treatment of chronic myeloid leukemia with BCR-ABL
gene fusion [2]. In solid tumors the response of ERBB2
gene amplified breast carcinomas to the anti-ERBB2
antibody trastuzumab is a further landmark in the
development of targeted therapies [3]. The efficacy
of tyrosine kinase inhibitors erlotinib and gefitinib in
the treatment of EGFR-mutated lung adenocarcino-
mas was a further boost for the concept of targeted
therapy [4, 5] and forced pathology departments to
implement EGFR mutation testing. In the meantime
the number of therapeutic targets and the require-
ments for genetic testing have increased (Table 1).
The development of molecular tumor subclassifi-
cations and targeted therapies was facilitated by an
improved knowledge of genetic aberrations. Although
cancer research has achieved great successes during
the last decades, e. g. the identification of oncogenes
and tumor suppressor genes, the genetic characterisa-
tion of tumors has gained a tremendous speed during
the last 10 years by the development of next genera-
tion sequencing (NGS) [6]. This technology brought
the capacity to analyse the genomes of a large num-
ber of tumors of different entities [7–9]. NGS enables
the simultaneous and rapid sequencing of millions of
DNA molecules at reduced costs. The first sequenc-
ing of the human genome with the traditional Sanger
technology required approximately 13 years at a cost
of about 3 bn US$ [10, 11]. NGS can analyse a human
genome within a week at a cost close to 1000 US$.
The currently most potent Sanger-based sequencers
analyse 1–2 megabases per day, whereas even small
bench top NGS instruments sequence 3–15 gigabases
per day. A further advantage of NGS is the versatility
of applications. In addition to DNA sequence deter-
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Table 1 Genes routinely analysed for mutations in solid tumors in diagnostic molecular pathology (selection)
Tumor Altered genes Therapy (selection)
Lung adenocarcinoma EGFR Gefitinib, erlotinib, afatinib, osimertinib
ALK Crizotinib, ceritinib
ROS1 Crizotinib
MET exon 14 Crizotinib
Gastrointestinal stroma tumor (GIST) KIT Imatinib, sunitinib
PDGFRA Imatinib, sunitinib
Colorectal carcinoma KRAS, NRAS, BRAF, MSIa Cetuximab, panitumumab, immune checkpoint inhibitor
Malignant melanoma BRAF Vemurafenib, dabrafenib, trametinib, cobimetinib
KIT Imatinib, sunitinib, dasatinib
Breast carcinoma HER2 Trastuzumab, pertuzumab
Ovarian carcinoma; triple negative breast carcinoma BRCA1/2 Olaparib
Medullary thyroid cancer RET Vandetanib
aMicrosatellite instability
Table 2 Applications of liquid biopsy in tumor diagnostics
Indications
Identification of resistance mutations
Identification of targets for therapy
Monitoring of tumor load
Monitoring early response to therapy
Monitoring of “minimal residual disease”
Assessment of molecular tumor heterogeneity
Early tumor detection
mination it is applicable for the detection of amplifi-
cations, deletions, gene fusions, DNAmethylation and
gene expression. Furthermore NGS is scalable; it can
be adjusted to gene panels, the human exome (≈1.5%
of the genome, ≈4.5 × 107 bases) or the whole genome
(≈3 × 109 bases).
The massive genomic characterisation of tumors
has been led by the The Cancer Genome Atlas (TCGA;
http://cancergenome.nih.gov/) and the International
Cancer Genome Consortium (ICGC; https://icgc.
org/). TCGA has studied more than 10,000 speci-
mens of 33 different tumor entities on the DNA, RNA
and epigenome level [12]. The ICGC is a joint effort
of 22 countries with the aim to analyse a total of
25,000 specimens from 50 different tumor entities.
The results of TCGA and ICGC are freely available to
the public (https://gdc.cancer.gov/ and https://dcc.
icgc.org/).
It is often difficult to distinguish mutations from
polymorphisms. Therefore efforts that identify poly-
morphisms are important for tumor diagnostics. The
1000 Genomes Project (http://www.1000genomes.
org/) has generated a catalogue of genetic variants
from 2504 people of 26 populations in 5 continental
regions with the aim to identify most of the polymor-
phisms that occur at a frequency of at least 1% [13].
The International Genome Sample Resource (http://
www.internationalgenome.org/home) continues the
1000 Genomes Project. A further valuable initiative
for the interpretation of tumor genome sequences
are the databases of Short Genetic Variations (dbSNP)
and Genomic Structural Variations (dbVar) of the
NCBI (https://www.ncbi.nlm.nih.gov/snp; https://
www.ncbi.nlm.nih.gov/dbvar).
At present single gene analysis with mutation-spe-
cific PCR and Sanger- or pyrosequencing [14] predom-
inates in diagnostic molecular pathology. However
gene panel sequencing with NGS increases rapidly.
These gene panels are either adapted for a tumor
entity and encompass the most frequent predictive
and prognostic mutations for that entity or represent
larger pan-cancer panels that covermost of the known
tumor driver genes [15].
The analysis of NGS data is challenging. In re-
cent years commercially available software tools have
improved and permit individuals with basic bioinfor-
matic proficiency to interpret NGS data. The more
demanding NGS applications like transcriptome se-
quencing or gene copy analysis however require bioin-
formatic professionals. Therefore pathology depart-
ments have to recruit and integrate bioinformaticians
to master the increasing demand for genetic tumor
profiling.
Currently molecular pathology adopts also the
analysis of cell-free DNA (cfDNA), which is released by
dying normal or tumor cells into the blood [16]. The
analysis of cfDNA can substitute for a tissue biopsy in
certain indications. Therefore the expression “liquid
biopsy” has been coined. However, it has to be em-
phasized that at least for the initial tumor diagnosis
a tissue biopsy is essential. The biggest challenge in
the analysis of cell-free tumor DNA (ctDNA) is the
often low frequency of mutated alleles in cfDNA. The
amount of ctDNA is variable and ranges from 0.01%
to more than 50% of the whole cfDNA. An advantage
of liquid biopsy is the low burden for the patient as
compared to tissue biopsy with a blood draw of 5 to
10ml. Furthermore, tumors possess an intratumoral
and intermetastatic genetic heterogeneity [17]. A tis-
sue biopsy therefore often does not capture the whole
spectrum of genetic changes of a tumor. The ctDNA
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however may better represent the genetic compo-
sition of different tumor compartments. A further
advantage is that DNA modifications caused by for-
malin fixation of tissue and the resulting artefacts in
DNA sequencing [18] are not present in ctDNA. A liq-
uid biopsy can be utilised for various indications in
tumor patients (Table 2), although most applications
are still in clinical validation. The major methods to
detect mutations in ctDNA are allele-specific PCR and
NGS. PCR methods with a particularly high sensitivity
are necessary, such as droplet digital PCR, for which
a lower detection limit of 0.01% mutated allele fre-
quency has been reported [19]. NGS protocols have
to be adapted for liquid biopsy, e. g. by tagging DNA
fragments with unique molecular barcodes [20], to in-
crease the sensitivity of mutation detection. In tumor
pathology at present only the detection of resistance
mutations, in particular in adenocarcinomas of the
lung, is clinical routine. EGFR-mutated lung ade-
nocarcinomas with secondary resistance to tyrosine
kinase inhibitors exhibit in approximately 60% a sec-
ondary T790M EGFR mutation. This mutation can be
detected in 70% of cases in ctDNA [21]. Patients with
this mutation can profit from third generation EGFR
inhibitors, such as osimertinib, that are able to block
T790M mutated EGFR.
Circulating tumor cells (CTC) are very scarce in the
blood. Mostly less than 10 CTC are present in 1 ml
blood in patients with metastasis [22]. In comparison
to ctDNA the utilisation of CTC for the detection of
somatic mutations is not clinical routine diagnostics
because of the very low amount of available DNA and
the high equipment and technical skill requirements.
The challenges in molecular pathology require
a new type of pathologists. The pathologists of the
future need to combine morphological methods with
practical and theoretical knowledge in genetics, cell
biology, biochemistry and bioinformatics. The uni-
versity departments of pathology will have to fulfill
a leading role in training surgical and molecular
pathology. The establishment of molecular pathol-
ogy requires space, equipment and personal. Their
financing is particularly difficult for smaller insti-
tutes. Therefore not all institutes will be able to offer
a broad spectrum of molecular pathology diagnostics.
A concentration in larger institutes, mainly university
departments, that serve as reference centers, is likely.
Molecular pathology tests are mostly performed
with formalin fixed and paraffin embedded tissues
(FFPE). The advantage is that the tissue blocks gen-
erated for histology can also be used for molecular
tests. A disadvantage is the fragmentation and chem-
ical modification of DNA by formalin [18]. Exome,
whole genome and transcriptome sequencing have
become feasible with FFPE tissue; however for these
applications fresh, unfixed tissue is still advantageous.
Therefore departments of pathology should establish
biobanks for the preservation of frozen, unfixed tis-
sues.
The future will bring an increase in molecular
pathology testing. The pace will be determined by
the availability of effective targeted drugs. Gene
panels will replace single gene analysis. Exome, tran-
scriptome and perhaps epigenome analysis will be
widely used and the applications of liquid biopsy
will expand. Furthermore proteome analysis and in
vitro drug susceptibility testing may become further
tasks. Molecular pathology will transform the clas-
sic morphology-based pathology. Pathologists will
become pilots for precision cancer therapy through
their unique ability to combine morphological and
molecular findings.
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